Recursion (RXRX): Growth-Adjusted Market Cap to Net Income

Recursion Pharmaceuticals (RXRX) is transforming drug discovery through the synergy of AI and automated biology. The PEG ratio trajectory on the GURU.Markets chart illustrates this technological breakthrough, where the parameter value equals 0.00. Supercomputer capacities and robo-labs ensure continuous data analysis. A team of visionary engineers and biologists is retained by a Silicon Valley culture and a stock option system.

Recursion (RXRX): Price/Earnings to Growth Ratio from 07/04/2022 to 11/10/2026

Recursion (RXRX) - metric breakdowns and financial figures

- share price and consensus valuation forecast:

Price Performance Chart Recursion Pharmaceuticals|RXRX - Price Target Chart

- stock exchange capitalization data:

Market Capitalization Recursion Pharma|RXRX - Enterprise Value

- company book value details:

Net Assets per Share Recursion|RXRX - Company Book Value|Market-to-Book Ratio recursion.com|RXRX - Aggregate Company Assets

- debt obligations and liquidity statistics:

Debt to Equity Ratio Recursion Pharmaceuticals|RXRX - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Recursion Pharmaceuticals, Inc.|RXRX - Company Debts|Debts to Book Capitalization Ratio Recursion Pharma|RXRX - Company Long-Term Debts|Company Short-Term Loans and Borrowings Recursion|Quick Ratio recursion.com

- net income and valuation ratios data:

RXRX - Company Net Income|Expected Net Income Recursion Pharmaceuticals|RXRX - Price to Earnings Ratio|Projected Price to Earnings Recursion Corp|RXRX - PEG Multiple|EV/EBITDA Multiple Recursion Pharma|RXRX - Operating profit EBITDA|Net earnings per share for the last 12 months Recursion|RXRX - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months recursion.com|RXRX - Net earnings per share growth this year|Earnings growth forecast for next year Recursion Pharmaceuticals

Fundamental company analysis:Recursion Pharma - RXRX

The growth dynamics of the Recursion Pharmaceuticals (RXRX) AI drug discovery platform are reflected in the PEG ratio. This indicator compares the P/E multiple with the earnings growth rate, allowing for a determination of whether the price per unit of expansion is fair. A value below one signals that the asset is undervalued, making it attractive for long-term capital.

Competing companies